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Abstract
Background: In 2012, the United States Preventative Services Task Force issued new guidelines recommending
that male U.S. residents, irrespective of race, no longer be screened for prostate cancer. In African American men,
the incidence of prostate cancer is almost 60 % higher and the mortality rate is two to three times greater than in
Caucasians. The purpose of this study is to reduce African American men's prostate cancer burden by demonstrating
they need separate screening guidelines.
Methods: We performed a PubMed search using the keywords: African American, Prostate cancer, Outcomes, Molecular
markers, Prostate-specific Antigen velocity, PSA density, and to derive data relevant to our hypothesis.
Results: In our literature review, we identified several aspects of prostate cancer that are different in Caucasian and
African American men. These included prostate cancer incidence and outcome, the clinical course of the disease, serum
PSA levels, genetic differences, and social barriers. It's also important to note that the USPSTF guidelines were based on
two studies, one of which reported that only 4 % of its participants were African American. The other did not report
demographic information, but used participants from seven European countries with small African American
populations.
Conclusion: Given the above, we conclude that separate prostate cancer screening guidelines are greatly
necessary to help save the lives of African Americans.
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Background
Prostate cancer represents the most common male vis-
ceral cancer in the United States. The estimated number
of annual new diagnoses and mortality in 2015 is
220,800 and 27,540, respectively [1]. The life time risk of a
diagnosis of prostate cancer is 15.9 % while the life time
risk of death is 2.8 % [2]. In African-American men, how-
ever, the incidence of prostate cancer is almost 60 % higher
and the mortality rate is two- to three-times greater than
that of Caucasian men. These numbers have remained re-
markably constant for more than 20 years [3].
A commonly held perception about prostate cancer in
the lay public and even within the scientific community
is that prostate cancer is generally an indolent disease
and therefore not as deadly because individuals who are
diagnosed with prostate cancer often die of other causes
unrelated to the cancer. Although this view may be true
to a certain extent when the at-risk U.S. population is
taken as a whole, it is our contention that it should not
apply to all prostate cancer patients, especially to those
of African-American descent. Because of differences in
the natural course of the disease and because of social
issues that differentially impact African Americans,
many of these patients may face a greater health burden
than their Caucasian counterparts once they have been
diagnosed [4–6]. Hence, a diagnosis that is made as early
as possible in this population may improve overall pros-
tate cancer outcomes. In this regard, we believe that the
current prostate cancer screening guidelines promul-
gated by the U.S. Preventative Services Task Force
(USPSTF) do not adequately take into account ethnic/
racial differences in the impact of prostate cancer on the
population. Separate screening guidelines for African
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American men would facilitate earlier diagnosis and
thereby reduce their mortality rate from the disease.
Hypothesis
African American men need separate screening guide-
lines to help decrease their prostate cancer burden.
Methods






Prostate-specific antigen (PSA) velocity
PSA density
We did not place any time restrictions. Specifically, we
used the word “African American” and then one of the
other five words listed above to create a total of four
combinations total. The articles derived from the initial
search were culled to identify peer-reviewed publications
that were relevant to the clinical, social, and health policy
aspects of the diagnosis and treatment of prostate cancer
in African American men. These manuscripts were then
analyzed closely to derive other sources of information
and data that were relevant to our hypothesis.
In our review of the literature, we identified several as-
pects of prostate cancer that are different in Caucasian
and African-American males. These included prostate
cancer incidence and outcomes, the clinical course of
the disease itself, serum PSA levels, and social barriers/
behaviors. These are discussed in more detail in subse-
quent sections below.
Results/Discussion
In 2012, the USPSTF issued new guidelines recommending
that U.S. male residents, irrespective of their race, no lon-
ger be screened for prostate cancer using PSA. In early
2015, the American Cancer Society recommended men
who are considering being screened for prostate cancer
should make an informed decision only after discussing
their prostate cancer specific risk factors and general
clinical situation, considering variables such as overall
health, performance status, and the presence or absence
of medical comorbidities, with their physician. There
are several differences between African American and
Caucasian men that make such guidelines ineffective
for African Americans.
Incidence of prostate cancer among African Americans
The incidence of prostate cancer among African American
males is higher than in any ethnic/racial group in the
United States. In fact, worldwide, those men with West
African ancestry have a disproportionately larger burden
of prostate cancer [3]. In the United States, the incidence
of prostate cancer in African American males has been
60 % higher than the incidence in Caucasians [3]. Further-
more, there are sociological aspects that adversely affect
the incidence of prostate cancer in African American
males. These will be discussed in sections below.
Clinical course of prostate cancer in African Americans
The course of prostate cancer has been shown to be dif-
ferent in African American men; for instance, prostate
cancer volume is greater in African American men and
advanced metastatic prostate cancer occurs at a 4:1 ratio
in black and white men, respectively [7]. While clinical
characteristics do not differ by race at an early age, pros-
tate cancer transforms earlier in black men (from indo-
lent to aggressive). Therefore, one can surmise that the
growth or transformation rate of prostate cancer is
greater in black men. Because of this augmented growth
rate, African American men likely present at a later stage
of disease than Caucasians at a similar age. Additionally,
among African American patients who had prostate biop-
sies without histological evidence of prostate cancer, their
PSA values were about 1.8-fold higher than those in whites,
even when controlling for prostate volume [8]. Genetically,
there seem to be differences between African American
and white males as well. For example, it has been suggested
that African American men may be more susceptible to
prostate cancer because of differences in the expression of
the androgen receptor genes [9]. Additionally, several risk-
associated single nucleotide polymorphisms (SNPs), appear
to be differentially overexpressed in African American men
compared to control subjects [10].
Social Differences in the African American Population
African American men face several social barriers that
Caucasian men may not, contributing further to their
risk of poorer prognoses and outcomes. For example,
when comparing men over the age of 50, only 81 % of
African Americans are likely to have health insurance
compared to nearly 90 % of Caucasians. This difference
is statistically significant [4]. African American men have
been noted to be less likely to be treated for prostate
cancer when compared to white patients with a similar
stage of disease [6]. Financial barriers associated with a
lower socioeconomic status (SES) are also a major con-
tributor to racial disparities in prostate cancer outcomes
[10, 11]. Nonfinancial related barriers such as poor
health seeking behaviors often can delay a prostate can-
cer diagnosis in African American men [5]. Thus, an in-
herent fear of a cancer diagnosis coupled with a mistrust
of the health care system at large, can significantly affect
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the outcome of African-American men with prostate
cancer [5].
Diets high in fat content have been associated with an
increased risk of prostate cancer. Specifically, a diet higher
in saturated fats is positively correlated to an increased
risk of prostate cancer. When considering Caucasians,
Asians, and African Americans, African Americans gener-
ally tend to consume more saturated fats and a greater
number of calories in their daily diet [9]. This dietary dis-
crepancy alone may account for almost 10 % of the differ-
ence in prostate cancer incidence between Caucasian and
African American men [12].
PSA levels are higher among African Americans
In general, African American men present with higher
PSA values when compared to white men [13]. Several
studies have shown that African American men with
nonmetastatic prostate cancer have higher serum PSA
levels at diagnosis than Caucasian men with nonmeta-
static prostate cancer, suggesting that perhaps African
Americans have a higher tumor cell burden [13, 14]. Fur-
thermore, African American men with or without evidence
for prostate cancer have a higher PSA density (when the
prostate is controlled for volume) than Caucasians [8, 13].
However, the differences between African Americans and
Caucasians in PSA velocity is controversial (assuming there
is any difference at all). In one study, Caucasians had
higher PSA velocities than African American men of a
similar age, despite the fact that African Americans had a
higher baseline PSA value, age-for-age [15]. This finding
could be attributed to laboratory test access as perhaps
African American men may have had fewer PSA tests over
time, thus impacting their velocity score despite higher
individual PSA values. Another study, reported that PSA
velocity is higher in Caucasians only in the 60–69 age
bracket, whereas in the 40–49 age group, PSA velocity is
higher in African Americans. Nonetheless, despite the fact
that PSA levels, density, and velocity appear different in
African-American men compared to Caucasians, the
USPSTF has issued guidelines that are not race specific.
Mortality rate
An undeniable certainty is that regardless of previous
screening recommendations, African American men
have had a higher mortality rate from prostate cancer
(two- to three-fold higher) and are carrying a larger
prostate cancer burden than their Caucasian contempor-
aries [7]. African American men also are less likely to
have health insurance and a higher proportion of them
are of lower SES. In regards to SES, however, its impact
on prostate cancer outcomes is controversial. For in-
stance, Xu et al. reported that after adjusting for SES,
the differences in prostate cancer mortality were elimi-
nated. This is particularly relevant to screening because
even among African Americans, screening guidelines
may differ based on SES [4, 10, 11].
USPSTF recommendation
In the past (2008), the USPSTF had stated there was insuf-
ficient evidence on the pros and cons of prostate cancer
screening for men below age 75 (Grade I —insufficient
knowledge of risks of the service), but that at and above
age 75, screening should not be performed (Grade D —
moderate or high risk of certainty that the service has no
net benefit or the risks outweigh the benefits). The pur-
pose of PSA screening is to reduce death rates directly
linked to prostate cancer by intervening with treatment;
however, screening and early treatment only benefited
anywhere from 0 to 1 man per 1,000 men screened [16].
Currently, however, the USPSTF is against PSA based
screening for male U.S. residents, regardless of ethnicity.
It considers PSA screening to be “Grade D.” Prostate can-
cer has a lifetime risk of diagnosis estimated to be 15.9 %,
while the lifetime risk of dying from prostate cancer is
2.8 % [2]. Thus, the argument is that many cases of pros-
tate cancer are likely to have a favorable outcome and un-
likely to impact survival, even without treatment or a
delayed diagnosis.
Another USPSTF argument against screening is that
even asymptomatic cancer is detected by PSA screening;
often, these tumors will not progress or will progress so
slowly that men are unlikely to experience deleterious
symptoms in their lifetime. This type of overdiagnosis or
pseudo-diagnosis is estimated to occur about 17 % to
50 % of the time in prostate cancer screening [16].
The USPSTF guidelines were based on two key studies:
The Prostate, Lung, Colorectal, and Ovarian Cancer
Screening Trial (PLCO) and the European Randomized
Study of Screening for Prostate Cancer (ERSPC). Ac-
cording to the USPSTF, the PLCO Trial reported that
only 4 % of enrolled men were non-Hispanic black
while the ERSPC study, based on populations in seven
countries with low populations of men of African des-
cent, did not report demographic statistics. From that
one can surmise that the majority of the subjects were
likely Caucasian [16].
Several studies examining the utility of screening have
generated differing findings. For example, the ERSPC
tried to answer the question of whether screening using
PSA leads to an improvement in cancer specific survival.
Remarkably, it noted that at 11 years of follow-up, 1,055
additional men would need to be screened and 37 extra
cases of prostate cancer would need to be detected to
prevent just one death from prostate cancer [17].
In the PLCO Trial, the men who underwent annual
prostate cancer screening with PSA and digital rectal
examination had a 12 % higher incidence of prostate can-
cer than men in the control group [18]. The rate of death
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due to prostate cancer, however, was equal amongst both
groups of men [18]. This study also found negative conse-
quences such as pain and bleeding being associated with
follow-up and treatment of abnormal screening tests [18].
The Prostate Cancer Intervention Versus Observational
Trial (PIVOT) study compared expectant management to
radical prostatectomy [19]. Its findings indicated that
there were no differences in outcomes of prostate cancer
in black men compared to white men [19]. Despite this
finding, however, black men have higher rates of mortality
due to prostate cancer. Moreover, only 30 % of its partici-
pants were identified as African American; hence, the trial
was likely under-powered due to selection bias and is not
generalizable to the African American community [19].
Although the general prostate cancer population as a
whole may have a strong proportion that is being over-
treated, African American men generally appear to be fa-
cing undertreatment and thus, the higher mortality rates.
Molecular Markers
Evidence for differences between the course and out-
come of prostate cancer in African American men also
has been found in molecular markers. Several studies
have been conducted regarding the location of SNPs and
the differences in their rates of occurrence by race. Ap-
proximately 100 genes with SNPs are implicated in in-
creasing men’s susceptibility to prostate cancer [20, 21].
These are especially accurate because SNPs are stable
throughout one’s lifetime, so they cannot be affected by
extraneous factors such as lifestyle [21]. Furthermore,
several biomarkers appear to distinguish between aggressive
and nonaggressive forms of prostate cancer; however, this
information is not incorporated into conventional forms of
prostate cancer screening [22]. The addition of genetic
markers to current clinical parameters likely will detect the
same number of prostate cancers without the need for a
needle biopsy, making personalized medicine more effective
and less invasive [23]. Unfortunately, African American
men appear to be at an increased risk for developing pros-
tate cancer in part because they possess several of these
genetic variations. For instance, Xu et al. have reported that
17 of the 20 SNPs they have examined are more common
in African American men and two of those 17 SNPs are
associated with a higher risk of developing prostate
cancer [24]. Other similar studies also have shown an
association between African American men and specific
genetic markers that appear to increase one’s suscepti-
bility for developing prostate cancer. For example,
Freedman et al., noted there is a 3.8 MB interval on
chromosome 8q24 that is associated with an increased
risk of prostate cancer [25]. This chromosome interval
is mainly found in African American men [25]. Individuals
with a family history of allelic variants in this region are
9.46 times more likely to develop prostate cancer than
someone without allelic variants [25].
Thus, despite the controversy associated with current
prostate cancer screening, African American men need
an updated set of screening guidelines that incorporate
what is currently being used for screening with cutting
edge molecular analyses to more successfully identify the
patients who are at an increased risk of prostate cancer.
Addressing the medical needs of such patients earlier
will contribute significantly to reducing the burden of
advanced disease, improve the chances of successful
treatment, and lower the associated treatment costs.
Other considerations
In 2013, the American Urological Association mentioned
that African American race is considered to be a risk
factor for prostate cancer, and that screening with PSA
should be individualized based on personal preference and
an informed discussion with health care providers after
weighing the costs versus the benefits associated with
screening [26]. We believe that this statement is not
robust enough for African Americans. The American
Urological Association’s stance has alluded to the fact that
due to the difference in disease course, there ought to be
some differences in the approach to screening for prostate
cancer; however, we propose that this statement under-
states the necessity and importance of separate screening
guidelines by failing to address the differences in disease
course between African Americans and Caucasians.
The National Comprehensive Cancer Network and the
American Cancer Society both also report that African
American race is considered to be a risk factor for prostate
cancer but they do not provide personalized screening
guidelines [27, 28]. The American Cancer society goes one
step further stating that African American men should
begin discussions with their physician at age 45 (5 years
earlier than men at average risk) [28]. However, neither
the National Comprehensive Cancer Society nor the
American Cancer Society have provided guidelines that
meet the needs of African American men using an indi-
vidualized approach.
It is also important to note that the lifetime risk of
dying due to prostate cancer is approximately 3 % and
men diagnosed with low to intermediate risk prostate
cancer are unlikely to have a compromised lifespan due
to said diagnosis [29]. Men with high risk prostate
cancer do benefit from treatment if their projected life
expectancy is greater than 10 years, but the majority of
men who are diagnosed with high risk prostate cancer
also have life expectancy of less than 10 years due to
causes unrelated to their prostate cancer [27]. Hence, it
is understandable that many individuals believe that
prostate cancer is generally indolent and men who are
diagnosed with prostate cancer often die of other causes
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unrelated to the cancer. However, it is our contention
that this view is not generalizable to all prostate cancer
patients as this data is derived from the entire male US
population as opposed to considering just men of African
American descent. Studies show that African American
men with lower educational attainment have lower rates
of prostate cancer screening; this discrepancy can in part
be explained by a fatalistic attitude [30]. These fatalistic
notions further highlight the importance of race specific
guidelines for the African American community. By
having separate screening guidelines, we can potentially
overcome fatalism in African Americans regardless of
their educational attainment and improve their survival.
It has been shown that African Americans have higher
PSA levels in cancerous tumors [14, 31–35]. Even in
non-cancerous prostates, African Americans have higher
PSA levels [13, 36]. Furthermore, a large national cohort
study found that African American veterans aged 40–54
were more likely to have 3 or more positive core biopsies
yet they were less likely to be actively surveilled when
compared to their white counterparts [36]. Indeed, African
American veterans, aged 55–70, were more likely to have
a higher grade and stage prostate cancer than African
American veterans aged 40–54 [36]. There is new evi-
dence, however, that highly undifferentiated tumors in
African Americans may secrete less PSA [37]. This
finding needs to be further explored, and the diversity
of data available on this topic highlights the need for
personalized guidelines.
Finally, it is crucial to consider that the current ad hoc
approach to treatment of prostate cancer in African
Americans is unreliable and needs to be better tailored.
For example, Pietzak et al. found that the current criteria
to evaluate which patients would benefit from active sur-
veillance are not reliable in appropriately selecting African
Americans when compared to Caucasians [38]. Kryvenko
et al. found that over half of diagnosed prostate cancers
considered to be insignificant (based on the Epstein cri-
teria) were actually misclassified, in part due to a greater
frequency of anterior tumors in African Americans com-
pared to the tumors of white men [39]. Lastly, Sundi et al.
have reported that African American men with very low
risk prostate cancer at diagnosis still have a significantly
higher prevalence of cancer at the anterior focus along
with a higher grade and larger volume when compared to
Caucasians [40].
Conclusion
We have shown that the general prostate cancer screening
guidelines developed by the USPSTF may be inappropriate
for African American men because the course of the
disease is different for them due to social and genetic
characteristics. Furthermore, African American men ap-
pear to intrinsically have a higher incidence of prostate
cancer and higher rates of mortality. It is important to
note that currently there is no cure for metastatic prostate
cancer and unfortunately, African American men are the
most likely individuals to present with aggressive prostate
cancer at initial diagnosis that advances to metastatic
prostate cancer [7]. At the same time, there are subsets of
African American patients who may not need aggressive
treatment at all, similar to the fair portion of the general
population diagnosed with prostate cancer. Both these
groups of patients are not readily identified and thus, the
screening recommendations have to be examined separ-
ately from treatment recommendations [41]. Given the
above, we conclude that separate prostate cancer screening
guidelines are important if we are to improve outcomes
and save the lives of of African American men. At this
time, we are working towards developing such guidelines
by conducting a survey among national prostate cancer
specialists. These guidelines will be the subject of future
correspondence.
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